DUBLIN--(BUSINESS WIRE)--

Research and Markets(http://www.researchandmarkets.com/research/75ef8d/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011" report to their offering.

Multiple Sclerosis Thought Leader Panel #14 highlights a series of interviews conducted with experts in September, 2011. For this Panel Medpredict asked their Thought Leaders to engage in a thought exercise with them. The purpose was to designate their fantasy formulary, comprised of the top seven therapeutics, currently in the development pipeline, that they want to see available for use in the prevention/treatment of multiple sclerosis. They allowed Panelists to choose the class of drug, a specific drug (if they had a preference), the unmet needs to be addressed and the benefits that they expected their choices to deliver. The panel's responses are just as enlightening regarding what they would NOT put on their fantasy formularies.

Key Topics Covered:

Executive Summary Fantasy Formulary - Ground Rules And Scoring Multiple Sclerosis Fantasy Formulary Results (2011) Multiple Sclerosis Fantasy Formulary Results (2010) Data Tables Discussion - Preferred Product Classes Oral Immunomodulators B-Cell Inhibitors Neuroregeneration S1P Receptor Agonists Anti-Cd-25 (Anti-Il-2) Vla-4 Long-Term Immunosuppressants Discussion - Other Product Mentions Neuropathic Pain Ga Next Generation Ctla4 Microglial Activation Inhibition Stem Cells Bone Marrow Transplant Complement Activation Interferon Vaccines / Immune Tolerance Discussion - What Didn'T Make The List Thought Leader Discussions

For more information visit http://www.researchandmarkets.com/research/75ef8d/thought_leader_ins

See the article here:
Research and Markets: Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011

Comments are closed.